MENU
Aim higher

BUPI

BUPI – a long-acting lozenge with bupivacaine for pain relief of Oral Mucositis in cancer patients

Moberg Pharma and partners will further develop and commersialise BUPI - an innovative and superior long-acting treatment for cancer patients suffering from pain associated with Oral Mucositis (OM). BUPI will be evaluated in a phase III trial. The project will deliver a final product ready for registration and thereafter launch – with documented benefits for patients.
Acronym: 
BUPI
Project ID: 
9 794
Ranking: 
74
Cut-off: 
3
Start date: 
01-10-2015
Project Duration: 
36months
Project costs: 
1 590 000.00€
Technological Area: 
Cytology, Cancerology, Oncology
Market Area: 
Therapeutic